Super Important Biotech and Drug Stock Events for November
BOSTON ( TheStreet) -- The November calendar of biotech and drug stock events.
Nov. 3
Earnings: Arena Pharmaceuticals (ARNA) - Get Report , MannKind (MNKD) - Get ReportNeurocrine Biosciences (NBIX) - Get Report
Nov. 4
Earnings: Ironwood Pharma (IRWD) - Get Report , Jazz Pharma (JAZZ) - Get Report , Halozyme Therapeutics (HALO) - Get Report , Exelixis (EXEL) - Get Report , Myriad Genetics (MYGN) - Get Report , Pharmacylics (PCYC) , Regeneron Pharma (REGN) - Get Report
FDA releases briefing documents for Oncologic Drug Advisory Committee meeting scheduled for Nov. 6: Rockwell Medical (RMTI) - Get Report (Triferic) and Novartis (NVS) - Get Report (Faridak.)
Nov. 5
Earnings: Actavis (ACT) - Get ReportRegulus Therapeutics (RGLS) - Get Report , Vivus (VVUS) - Get Report , Alnylam Pharma (ALNY) - Get Report
FDA approval decision: Aeterna Zentaris (AEZS) - Get Report Macrilen for growth hormone deficiency.
The Medicines Co. (MDCO) - Get Report Investor/Analyst meeting.
Nov. 6
Earnings: Amarin (AMRN) - Get Report , AstraZeneca (AZN) - Get Report , Epizyme (EPZM) - Get Report , Hyperion Therapeutics (HPTX) Keryx Pharma (KERX) - Get Report , Medivation (MDVN) , NewLink Genetics (NLNK) - Get Report , Raptor Pharma (RPTP) , Tekmira Pharma (TKMR) , Spectrum Pharma (SPPI) - Get Report , Sarepta Therapeutics (SRPT) - Get Report
FDA Oncologic Drugs Advisory Committee: Rockwell Medical (Triferic) and Novaris (Faridak.)
Nov. 7
Earnings: Agios Pharma (AGIO) - Get Report , Intercept Pharma (ICPT) - Get Report
Nov. 10
Intercept Pharma Analyst/Investor Day.
Nov. 13
Earnings: Retrophin (RTRX) - Get Report
Nov. 18
AstraZeneca Analyst/Investor Day
Ligand (LGND) - Get Report Analyst/Investor Day
Nov. 19
FDA approval decision: Genentech/Roche (RHHBY) Avastin for recurrent, platinum-resistant ovarian cancer.
Nov. 26
FDA approval decision: Avanir Pharma (AVNR) AVP-825 for migraine.
November Medical Meetings:
Nov. 2-7: Obesity Week: Orexigen Therapeutics (OREX) , Arena Pharma ARNA
Nov. 7-11: American Association for the Study of Liver Disease (AASLD): Gilead Sciences (GILD) - Get Report , Merck (MRK) - Get Report , Bristol-Myers Squibb (BMY) - Get Report , Abbvie ABBV, Enanta Pharma (ENTA) - Get Report , Arrowhead Research (ARWR) - Get Report , Conatus Pharma (CNAT) - Get Report , Genfit ALGFT, Alnylam Pharma (ALNY) - Get Report
Nov. 9: International Gynecologic Cancer Society: Oxigene (OXGN) fosbretabulin+Avastin phase II recurrent ovarian cancer.
Nov. 11-16: American Society of Nephrology: Acceleron Pharma (XLRN) - Get Report
Nov. 13-16: Society of Neuro-Oncology annual meeting: Celldex Therapeutics (CLDX) - Get Report , ImmunoCellular Therapeutics (IMUC)
Nov. 15-19: American Heart Association Scientific Sessions: Merck, NeoStem (NBS) , Regeneron Pharma
Nov. 18-21: EORTC-NCI-AACR: Agios Pharma, Bind Therapeutics (BIND) , Clovis Oncology
Clinical Data:
XOMA (XOMA) - Get Report Gevokizumab (Behcet's Syndrome), Achillion Pharma (ACHN) - Get Report ACH-3422 (hepatitis C)
Source: BioMedTracker.com, company reports and TheStreet research.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
